Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov and CTIS registry records · Last verified 26 Sep 2026 · Editorial standards

At a glance

Second Affiliated Hospital of Nanchang University is the lead sponsor of 36 current clinical trials in our China register. 25 are recruiting patients now. The most common phase is Observational. The drugs named most often in its trials are Spironolactone, Adebrelimab and Apatinib. The most-studied condition is Atrial Fibrillation (AF).

ClinicalTrials.gov trials by status

Recruiting2569%
Not yet open38%
Active, closed411%
By invitation411%

Trials by phase

Observational1336%
Not applicable1233%
Phase 2514%
Phase 438%
Phase 2/313%
Phase 1/213%
Phase 313%

Clinical trials sponsored by Second Affiliated Hospital of Nanchang University

36 on ClinicalTrials.gov

Study	Phase	Status	Start	Registers
SFRT+Tislelizumab+Platinum Chemotherapy for Unresectable Stage III NSCLC NCT07131319 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer	Phase 2/3	Recruiting	2025-04	China
Research on the Application of Nursing Intervention Based on ITHBC Theory in Postoperative Self-Management of Patients With Varicose Veins of the Lower Extremities NCT07570277 · ClinicalTrials.gov ↗ · Varicose Veins	Not applicable	Recruiting	2025-05	China
Analysis of Influencing Factors of High-Order Aberrations of SMILE With Lenticule Retained NCT06806085 · ClinicalTrials.gov ↗ · Small-incision Lenticule Extraction (SMILE) Surgery, Corneal Higher-order Wavefront Aberrations, Residual Lenticule	Observational	Recruiting	2024-10	China
Clinical Efficacy and Mechanism Exploration of MR-61 in Delaying the Progression of Myopia NCT07298824 · ClinicalTrials.gov ↗ · Myopia Progressing	Phase 2	Recruiting	2025-10	China
Diagnostic Performance of an AI-based Model for TCM Constitution Classification Using Ophthalmic Imaging NCT07127939 · ClinicalTrials.gov ↗ · Ophthalmic Imaging, Deep Learning, Artificial Intelligence (AI)	Observational	Recruiting	2025-07	China
ML Models Predicting Cycloplegic Refractive Error Based on Non-Cycloplegic Parameters in Myopic Adults NCT07690813 · ClinicalTrials.gov ↗ · Refractive Errors, Cycloplegic Refraction, Accommodation	Observational	Recruiting	2023-10	China
Double-Dose Third-Generation EGFR-TKI Plus Bevacizumab and Intrathecal Chemotherapy for Refractory Leptomeningeal Metastatic NSCLC: A Phase II Study NCT07398599 · ClinicalTrials.gov ↗ · Leptomeningeal Metastasis, Lung Neoplasms, Non-Small Cell Lung Cancer	Not applicable	Recruiting	2026-02	China
Study on the Diagnostic Efficacy of ICL Selection and Prediction Depth Model Based on Eye Images NCT06669728 · ClinicalTrials.gov ↗ · Posterior Chamber Phakic Intraocular Lens, Vault, Deep Neural Network	Observational	Recruiting	2021-01	China
Vebreltinib Plus Furmonertinib in Patients With EGFR-mutated Advanced Non-small Cell Lung Cancer and High PD-L1 Expression NCT07655622 · ClinicalTrials.gov ↗ · Non-Small-Cell Lung Cancer Drugs: Furmonertinib, Vebreltinib	Phase 1/2	Recruiting	2026-07	China
SFRT+Sequential Hypofractionated/Conventional Fractionated RT+Iparomlimab and Tuvonralimab for Relapsed/Refractory Solid Tumors NCT06936748 · ClinicalTrials.gov ↗ · Cancer	Phase 2	Recruiting	2025-06	China
Safety and Efficacy of Platelet-Rich Plasma Combined With Compound Betamethasone in Arthroscopic Surgery for Rotator Cuff Injury With Shoulder Adhesion: A Prospective, Multicenter, Randomized Controlled Trial NCT07348016 · ClinicalTrials.gov ↗ · Rotator Cuff Injuries, Adhesions Drugs: Compound betamethasone, Liposomal bupivacaine	Not applicable	Recruiting	2025-08	China
Olanzapine Impact on First-line Immunotherapy for Advanced EGFR-negative NSCLC NCT06554613 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer Drugs: Nivolumab, Olanzapine, Opdivo	Phase 2	Recruiting	2024-07	China
Hemorrhage Stroke Decision Making Model Based Deep Learning (BrainHemoAI System) NCT07570680 · ClinicalTrials.gov ↗ · Hemorrhage Stroke	Observational	Recruiting	2022-09	China
The Effect of SAAE on Vascular Endothelial Function in PA Patients NCT05561361 · ClinicalTrials.gov ↗ · Primary Aldosteronism Drug: Spironolactone	Observational	Recruiting	2022-10	China
Predictive Performance of a Generative Model for Corneal Tomography After ICL Implantation NCT07146737 · ClinicalTrials.gov ↗ · ICL, Vault, Deep Learning	Observational	Recruiting	2025-07	China
Comparative Study on the Safety and Efficacy of Using AccuSafe Transseptal Guidewire Versus Traditional Transseptal Needle for Transseptal Puncture in non-or Free- Guidance NCT07515040 · ClinicalTrials.gov ↗ · Atrial Fibrillation (AF)	Not applicable	Recruiting	2025-02	China
Superselective Adrenal Arterial Embolization for Refractory Hypertension: A Proof-of-Concept Study NCT06568640 · ClinicalTrials.gov ↗ · Essential Hypertension	Not applicable	Recruiting	2024-08	China
Phenotypic Age Acceleration (PhenoAgeAccel) for Joint Prediction of Disease Risk, Mortality Risk, Life Expectancy, and Disease-Free Healthspan in Major Chronic Diseases NCT07595094 · ClinicalTrials.gov ↗ · Phenotypic Age Acceleration, Biological Aging Marker, Mortality Risk Prediction	Observational	Recruiting	2006-06	China
The Effect of SAAE on Ventricular Remodeling in PA Patients NCT05501080 · ClinicalTrials.gov ↗ · Primary Aldosteronism Drug: Spironolactone	Not applicable	Recruiting	2022-09	China
Clinical Efficacy and Safety of Left Bundle Branch Area Pacing Using Quantitative Guidance of Multimodal Data in the Treatment of Heart Failure NCT07814612 · ClinicalTrials.gov ↗ · Heart Failure, Left Bundle Branch Block, Non-ischemic Cardiomyopathy	Not applicable	Recruiting	2024-03	China
Clinical Risk Score Prediction for Risk of Dementia Among Late-life Population With Depression NCT07676851 · ClinicalTrials.gov ↗ · Alzheimer Dementia (AD), Dementia, Late Life Depression (LLD)	Observational	Recruiting	2006-06	China
Diagnostic Efficacy of CNN in Predicting Intraoperative Complications and Postoperative Outcomes in SMILE NCT06204926 · ClinicalTrials.gov ↗ · Deep Convolutional Neural Network, Small-incision Lenticule Extraction (SMILE) Surgery, Intraoperative Complications	Observational	Recruiting	2021-06	China
Multi-Center Registry Cohort Study on Prognostic Factors and Prediction Model Construction in Aneurysmal SAH NCT05738083 · ClinicalTrials.gov ↗ · Aneurysmal Subarachnoid Hemorrhage	Observational	Recruiting	2018-10	China
The Impact of Semaglutide Compared to Energy Restriction on Type 2 Diabetes NCT07272343 · ClinicalTrials.gov ↗ · Type 2 Diabetes Mellitus (T2DM), Semaglutide, Caloric Restriction	Phase 4	Recruiting	2023-02	China
Early Lumbar Drainage Plus Intrathecal Urokinase in Severe Aneurysmal Subarachnoid Hemorrhage (LD-ITUK) NCT06284642 · ClinicalTrials.gov ↗ · Aneurysmal Subarachnoid Hemorrhage Drug: Urokinase	Phase 4	Recruiting	2024-03	China
Deep Sedation vs. General Anesthesia for Pulsed Field Ablation in Atrial Fibrillation NCT07621432 · Atrial Fibrillation (AF)	Not applicable	Not yet open	2026-05	China
Iparomlimab and Tuvonralimab Combined With SFRT and Definitive Chemoradiotherapy in Locoregionally Advanced Bulky HNSCC NCT07041788 · ClinicalTrials.gov ↗ · Cancer Drug: Iparomlimab and Tuvonralimab	Phase 2	Not yet open	2026-04	China
Early Lumbar Drainage for Intraventricular Hemorrhage NCT07625449 · ClinicalTrials.gov ↗ · Intraventricular Hemorrhage, Cerebral Hemorrhage	Not applicable	Not yet open	2026-10	China
To Observe the Clinical Efficacy of Traditional Chinese Medicine Compound(Weipi Formula ) in the Treatment of Epigastric Stuffiness Syndrome NCT06985524 · ClinicalTrials.gov ↗ · Functional Dyspepsia(FD) Was Studied	Not applicable	By invitation	2024-01	China
A Multicenter, Prospective, Randomized, Controlled Study of Decitabine in Combination With R-CHOP for Initial Treatment of EBV+ Diffuse Large B-cell Lymphoma NCT07348575 · ClinicalTrials.gov ↗ · Lymphoma, Large-Cell, Diffuse Drugs: Decitabine, R-Chop	Phase 3	By invitation	2024-07	China
Adjuvant Adebrelimab Plus Apatinib After Chemoradiation in Limited-Stage Small Cell Lung Cancer NCT06773156 · ClinicalTrials.gov ↗ · Limited-stage Small Cell Lung Cancer (LS-SCLC) Drugs: Adebrelimab, Apatinib	Phase 2	By invitation	2024-11	China
The Relation Between the Prognosis of Subthalamic Nucleus Deep Brain Stimulation Surgery by Microlesion Effect and Electrode Position NCT06685510 · ClinicalTrials.gov ↗ · Parkinson's Disease (PD), Deep Brain Stimulation	Observational	By invitation	2023-11	China
3D-Printed Grafts for Knee Cartilage Repair NCT07312175 · ClinicalTrials.gov ↗ · Osteochondral Lesions of Knee, Osteo Arthritis	Not applicable	Active, closed	2025-08	China
Ultrasound Large-scale Model in Thyroid Field: A Multi-center Study on Medical-Engineering Integration NCT07296575 · ClinicalTrials.gov ↗ · Thyroid Abnormalities, Thyroid, Thyroid Cancer	Observational	Active, closed	2025-10	China
A Clinical Study Evaluating the Efficacy and Safety of CreNeuriS CNS Herbal Nutrition Capsules for Participants With Mild Depressive Disorder Comorbid With Anxiety Disorder NCT07295444 · ClinicalTrials.gov ↗ · Mild Depressive Disorder Comorbid With Anxiety Disorder	Not applicable	Active, closed	2025-11	China
Clinical Study of Esketamine in Patients With Sepsis Undergoing Invasive Mechanical Ventilation NCT07556172 · ClinicalTrials.gov ↗ · Sepsis, Mechanical Ventilation Drugs: Esketamine, Remifentanil	Phase 4	Active, closed	2025-01	China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

Drugs in Second Affiliated Hospital of Nanchang University trials

16 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

Spironolactone2 Adebrelimab1 Apatinib1 Compound betamethasone1 Decitabine1 Esketamine1 Furmonertinib1 Iparomlimab and Tuvonralimab1 Liposomal bupivacaine1 Nivolumab1 Olanzapine1 Opdivo1 R-Chop1 Remifentanil1 Urokinase1 Vebreltinib1

Conditions in Second Affiliated Hospital of Nanchang University trials

62 conditions

Atrial Fibrillation (AF)2 Non-Small Cell Lung Cancer2Small-incision Lenticule Extraction (SMILE) Surgery2Deep Learning2Vault2Cancer2 Primary Aldosteronism2 Aneurysmal Subarachnoid Hemorrhage2Varicose Veins1Osteochondral Lesions of Knee1Osteo Arthritis1Corneal Higher-order Wavefront Aberrations1Residual Lenticule1Functional Dyspepsia(FD) Was Studied1Myopia Progressing1Ophthalmic Imaging1Artificial Intelligence (AI)1Traditional Chinese Medicine Constitution1Refractive Errors1Cycloplegic Refraction1Accommodation1Leptomeningeal Metastasis1Lung Neoplasms, Non-Small Cell Lung Cancer1Posterior Chamber Phakic Intraocular Lens1

By trial register

Register	Trials	Recruiting
Clinical trials in China	36	25

A trial with sites in more than one country appears in each of those registers.

Other sponsors in Atrial Fibrillation (AF)

Sponsor	Trials
Beijing Anzhen Hospital	13
Shanghai Chest Hospital	6
Jiangsu Taizhou People's Hospital	2
Hangzhou Dinova EP Technology	2
Lanzhou University Second Hospital	1

Sponsors with the most current trials registered for this condition.

Questions about Second Affiliated Hospital of Nanchang University trials

How many clinical trials does Second Affiliated Hospital of Nanchang University sponsor?

Second Affiliated Hospital of Nanchang University is the lead sponsor of 36 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Second Affiliated Hospital of Nanchang University trials recruiting?

Yes. 25 of its 36 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Second Affiliated Hospital of Nanchang University testing?

Its current trials name 16 drugs and biologicals as interventions. The most frequent are Spironolactone (2), Adebrelimab (1), Apatinib (1), Compound betamethasone (1) and Decitabine (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

Second Affiliated Hospital of Nanchang University clinical trials